Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 22, 2023

Paclitaxel ± Cixutumumab as Second-Line Treatment for Metastatic Esophageal or Gastroesophageal Junction Cancer

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
Oncologist 2023 Apr 27;[EPub Ahead of Print], S Stockton, P Catalano, SJ Cohen, BA Burtness, EP Mitchell, E Dotan, SJ Lubner, P Kumar, MF Mulcahy, GA Fisher, TL Crandall, A Benson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading